How to Tell When A Drug Company Fibs About Clinical Trial Results
By Adam Feuerstein,
The Street
| 07. 03. 2012
Osiris Therapeutics
"disappeared" important data when the company announced results Monday
from a mid-stage study of its stem cell therapy Prochymal in heart
attack patients.
Naturally, Osiris didn't come out and tell investors that it was
issuing a misleading press release on the Prochymal heart attack study.
Instead, the company claimed the study was a success. That's not true.
Figuring out Osiris' deception wasn't that difficult if you know how to
parse the language of clinical trial results and look at independent
sources of information for the truth.
Ride along with me as I pick apart Osiris' statements regarding the Prochymal heart attack study.
Interpreting clinical trial results with a skeptical eye is a crucial
tool for all biotech investors, so apply these skills universally
whenever a drug or biotech company tries to convince you that its drug
works. Hopefully, you'll find most companies are telling the truth, but
sadly and too often, bullish pronouncements about boffo clinical trial
data are just spin jobs ginned up to plaster over problems and bad data.
Here's what Osiris issued Monday:
Osiris...
Related Articles
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Carey Gillan, UnSpun | 03.18.2024
A Mexican standoff with the United States turned into a Mexican smack-down this month with the release of Mexico’s formal rebuttal to US efforts to overturn limits Mexico has ordered on the use of genetically modified (GM) corn and the...
By Billy Perrigo, TIME | 03.11.2024
The U.S. government must move “quickly and decisively” to avert substantial national security risks stemming from artificial intelligence (AI) which could, in the worst case, cause an “extinction-level threat to the human species,” says a report commissioned by the U.S...